HIV 感染者两剂次 SARS-CoV-2 信使 RNA 疫苗接种的安全性和抗体应答。
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.
机构信息
Department of Surgery.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine.
出版信息
AIDS. 2021 Nov 15;35(14):2399-2401. doi: 10.1097/QAD.0000000000003017.
Abstract
This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.
摘要
这项研究纳入了 14 名 HIV 感染者（PWH），结果表明，在接种两剂 SARS-CoV-2 mRNA 疫苗后，所有受试者的抗 SARS-CoV-2 受体结合域（RBD）抗体滴度均较高，尽管单剂接种后的滴度存在差异。大多数疫苗反应为轻度，且未发生不良事件。
相似文献
1
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.HIV 感染者两剂次 SARS-CoV-2 信使 RNA 疫苗接种的安全性和抗体应答。
AIDS. 2021 Nov 15;35(14):2399-2401. doi: 10.1097/QAD.0000000000003017.
2
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.艾滋病毒感染者接种首剂严重急性呼吸综合征冠状病毒 2 信使 RNA 疫苗的安全性和抗体反应。
AIDS. 2021 Sep 1;35(11):1872-1874. doi: 10.1097/QAD.0000000000002945.
3
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
4
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.AS03 佐剂新型冠状病毒 2 重组蛋白疫苗（CoV2 preS dTM）在健康成年人中的安全性和免疫原性：一项 2 期、随机、剂量发现、多中心研究的中期结果。
Lancet Infect Dis. 2022 May;22(5):636-648. doi: 10.1016/S1473-3099(21)00764-7. Epub 2022 Jan 25.
5
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.真实世界中衰弱老年人接受延长间隔和异源 COVID-19 mRNA 疫苗接种后的血清学反应（UNCoVER）：一项前瞻性观察队列研究的中期报告。
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
6
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.在免疫重建不良的 HIV 感染者中，SARS-CoV-2 疫苗接种后体液和特异性 T 细胞应答有限。
J Infect Dis. 2022 Nov 28;226(11):1913-1923. doi: 10.1093/infdis/jiac406.
7
Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?mRNA SARS-CoV-2 疫苗接种后抗刺突抗体的持久性在既往感染者中更长：是否可以延迟加强针接种？
Infection. 2022 Dec;50(6):1573-1577. doi: 10.1007/s15010-022-01816-9. Epub 2022 Apr 7.
8
Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals.感染 HIV 的个体接种 SARS-CoV-2 疫苗对 HIV-1 RNA 水平和抗体应答的影响。
Front Immunol. 2022 Feb 10;12:820126. doi: 10.3389/fimmu.2021.820126. eCollection 2021.
9
Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.接种两剂灭活 SARS-CoV-2 疫苗的医护人员接种第三剂 mRNA-1273 疫苗后的抗体反应。
Int J Infect Dis. 2022 May;118:116-118. doi: 10.1016/j.ijid.2022.02.036. Epub 2022 Feb 19.
10
Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.在常见变异性免疫缺陷个体中，第三和第四剂 SARS-CoV-2 疫苗后的抗体反应。
Front Immunol. 2022 Jul 28;13:934476. doi: 10.3389/fimmu.2022.934476. eCollection 2022.
引用本文的文献
1
Distinct immune responses in people living with HIV following SARS-CoV-2 recovery.SARS-CoV-2感染康复后的HIV感染者的不同免疫反应。
Commun Med (Lond). 2025 Apr 23;5(1):132. doi: 10.1038/s43856-025-00839-1.
2
Efficacy of COVID-19 Vaccination in People Living with HIV/AIDS in a Northern Brazil: Cross-Sectional Study.巴西北部艾滋病毒/艾滋病感染者中新冠疫苗接种的效果：横断面研究
Vaccines (Basel). 2025 Mar 7;13(3):283. doi: 10.3390/vaccines13030283.
3
Severe acute respiratory syndrome coronavirus-2 antibody prevalence in adults with HIV.成人艾滋病病毒感染者中严重急性呼吸综合征冠状病毒2抗体的流行情况
AIDS. 2025 Jul 15;39(9):1178-1184. doi: 10.1097/QAD.0000000000004180. Epub 2025 Mar 13.
4
Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa.利用南非哨兵监测估算针对与 SARS-CoV-2 相关住院的疫苗有效性。
Int J Epidemiol. 2024 Aug 14;53(5). doi: 10.1093/ije/dyae116.
5
COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis.COVID-19 突破性感染在 HIV 感染者中的研究：全州队列分析。
J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):107-116. doi: 10.1097/QAI.0000000000003475.
6
Serum SARS-CoV-2 antibodies in HIV-1-infected patients after inactivated vaccination and SARS-CoV-2 infection.HIV-1感染患者在接种灭活疫苗和感染SARS-CoV-2后的血清SARS-CoV-2抗体
Heliyon. 2024 May 23;10(11):e31731. doi: 10.1016/j.heliyon.2024.e31731. eCollection 2024 Jun 15.
7
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.在接种Ad26.COV2.S疫苗的参与者中，使用Ad26.COV2.S或BNT162b2进行加强免疫接种和分剂量接种的安全性和免疫原性。
PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703. eCollection 2024.
8
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.mRNA 疫苗接种对 HIV 病毒血症和储存库大小的影响。
AIDS. 2024 Jul 1;38(8):1120-1130. doi: 10.1097/QAD.0000000000003841. Epub 2024 Jan 22.
9
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.新型冠状病毒肺炎信使核糖核酸疫苗对艾滋病毒病毒血症和病毒库大小的影响。
medRxiv. 2023 Oct 9:2023.10.08.23296718. doi: 10.1101/2023.10.08.23296718.
10
The immune response to SARS-CoV-2 in people with HIV.人类免疫缺陷病毒（HIV）感染者对 SARS-CoV-2 的免疫反应。
Cell Mol Immunol. 2024 Feb;21(2):184-196. doi: 10.1038/s41423-023-01087-w. Epub 2023 Oct 11.
本文引用的文献
1
In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients.寻找新冠病毒（SARS-CoV-2）的保护相关指标：对预先确定的寡症状/无症状患者的两种定量S1检测方法进行直接比较
Infect Dis Ther. 2021 Jun 16:1-14. doi: 10.1007/s40121-021-00475-x.
2
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗的高抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
3
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.艾滋病毒感染者接种首剂严重急性呼吸综合征冠状病毒 2 信使 RNA 疫苗的安全性和抗体反应。
AIDS. 2021 Sep 1;35(11):1872-1874. doi: 10.1097/QAD.0000000000002945.
4
Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).意大利那不勒斯“帕斯卡尔基金会”癌症中心（INT - IRCCS）医护人员的疫苗接种策略及抗SARS-CoV-2 S抗体滴度
Infect Agent Cancer. 2021 May 12;16(1):32. doi: 10.1186/s13027-021-00375-2.
5
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.实体器官移植受者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗系列的抗体反应。
JAMA. 2021 Jun 1;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
6
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients.在接受治疗的癌症患者中，单剂新冠病毒mRNA疫苗后的免疫原性较弱。
Ann Oncol. 2021 Aug;32(8):1051-1053. doi: 10.1016/j.annonc.2021.04.020. Epub 2021 Apr 29.
7
Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.针对 SARS-CoV-2 刺突蛋白受体结合域的总抗体的快速高通量自动化电化学发光免疫分析与中和测定的比较性能。
J Clin Virol. 2021 Jun;139:104820. doi: 10.1016/j.jcv.2021.104820. Epub 2021 Apr 10.
8
Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.两种剂量的 SARS-CoV-2 疫苗在实体器官移植受者中的安全性和反应原性。
Transplantation. 2021 Oct 1;105(10):2170-2174. doi: 10.1097/TP.0000000000003780.
9
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.抗 SARS-CoV-2 抗体反应在接受英夫利昔单抗治疗的 IBD 患者中减弱。
Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22.
10
Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer.针对 COVID-19 疫苗接种者和未接种者的严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）抗体：来自同一制造商的两种不同商业可用血清学检测方法的比较方法。
Clin Chim Acta. 2021 Jul;518:9-16. doi: 10.1016/j.cca.2021.03.007. Epub 2021 Mar 17.
Zotero 插件